Invitation to comment on commercial release of genetically modified (GM) canola

Overview

The Gene Technology Act 2000, enacted by the Australian Parliament, establishes a regulatory framework to manage the potential risks associated with the development and commercial use of genetically modified organisms. This legislation aims to protect human health and the environment by ensuring that risks posed by gene technology are identified and managed effectively. The Act facilitates the assessment and licensing of activities involving genetically modified organisms, including the commercial release of genetically modified crops. The Gene Technology Regulator, established under the Act, oversees the assessment of applications and the implementation of risk management measures. The policy objective of the Act is to enable the safe and beneficial use of gene technology while safeguarding public health and the environment. In the context of the proposed commercial release of genetically modified canola by Monsanto Australia Ltd, the Act ensures that a comprehensive risk assessment and risk management plan is developed and that public consultation is conducted to inform the decision-making process.

Scope and Application

The legislation, C2014G01231, pertains to the assessment and potential commercial release of genetically modified (GM) canola in Australia, specifically Monsanto Australia Ltd's MON 88302 canola, which has been engineered for glyphosate tolerance. The Act applies to the entities involved in the application and assessment process, including the Gene Technology Regulator, Monsanto Australia Ltd, and any interested parties invited to submit comments. Geographically, the scope of the Act is national, with the potential commercial release of the GM canola subject to any state government restrictions imposed for marketing purposes. The Act’s purpose is to ensure that any risks associated with the release are identified and managed to protect human health and safety, as well as the environment. The consultation document, which includes a Risk Assessment and Risk Management Plan (RARMP), concludes that the proposed release poses negligible risk. The Act invites written submissions to finalise the RARMP before a decision on whether to issue a licence is made. Exclusions, exemptions, or thresholds are not explicitly detailed in the provided text, though it is implied that the Gene Technology Regulator will determine these through the assessment process and potential licence conditions.

Key Provisions

The main operative sections of this legislation concern the assessment and potential commercial release of genetically modified (GM) canola in Australia. Section 1 outlines the purpose of the Gene Technology Act, which is to safeguard health and environmental safety through the management of risks associated with gene technology (s. 3). Section 2 details the process for assessing licence applications for the commercial release of GM organisms, including the requirement for a Risk Assessment and Risk Management Plan (RARMP) (s. 12). Section 3 specifies the conditions under which the commercial release can occur, which must be approved by the Gene Technology Regulator (s. 15). These sections collectively establish the framework for evaluating the safety and potential environmental impact of GM canola before it can be released into the commercial market. The obligations imposed by the Act require the Gene Technology Regulator to thoroughly assess the risk associated with the proposed GM canola, as detailed in the RARMP. The Regulator must ensure that any potential risks to human health and the environment are identified and managed effectively. Additionally, the applicant, in this case Monsanto Australia Ltd, must provide comprehensive data and evidence to support their application for a commercial release licence. The Regulator is also mandated to consult with the public and stakeholders during the assessment process, as evidenced by the invitation for written submissions to finalise the RARMP (s. 18). Furthermore, the Regulator must consider any restrictions imposed by State governments for marketing reasons and integrate these into the licence conditions, if applicable (s. 16). Breaching the provisions of the Act can result in significant consequences. The Act provides for both civil and criminal penalties for non-compliance. For instance, unauthorised commercial release of a genetically modified organism can lead to criminal charges, with potential penalties including substantial fines and imprisonment (s. 63). Civil penalties can also be imposed for breaches, with fines up to a maximum of $1.1 million for corporations and $220,000 for individuals, depending on the severity and intent of the breach (s. 62). Additionally, the Regulator has the authority to impose conditions on the licence to ensure compliance, and failure to adhere to these conditions can result in the licence being revoked or amended, effectively halting the commercial release of the GM canola (s. 22). The Act aims to ensure that all parties involved in the gene technology process adhere to stringent safety and regulatory standards to protect public health and the environment.